M.A. and B.A., economics, Université Laval
Summary of Experience
Ms. Fournier specializes in pharmaceutical and health economics. She has extensive experience analyzing large data sets, including government and private administrative claims records. She has also conducted economic and statistical analyses for a wide variety of health care-related litigations. She has supported counsel on issues related to alleged kickbacks, off-label marketing, and delayed generic entry, among others. Her recent case experience has involved assisting experts in the preparation of reports, testimony, and related analyses in connection with class certification and damages. Ms. Fournier has presented a number of abstracts and published on health economics topics, including medical costs of various illnesses and drug cost-effectiveness. In 2015, she contributed to a landmark study on the societal costs of depression, published in the Journal of Clinical Psychiatry.
PharmacoEconomics (2021) 39:617
J Clin Psychiatry 2015 Feb;76(2):155-73
The Economic Impact of Pre-Dialysis Epoetin Alfa on Health Care and Work Loss Costs in Chronic Kidney Disease: An Employer's Perspective
Disease Management 2008 Feb;11(1):49-58
Medical and work loss burden of pre-dialysis chronic kidney disease and related anemia: an employer's perspective
Journal of Health & Productivity 2007 (Oct): 3-9
Prevalence, referral patterns, testing, and surgery in aortic valve disease: leaving women and elderly patients behind?
J Heart Valve Dis 2007 Jul;16(4):362-9
The Impact of Antihypertensive Drugs on the Number and Risk of Death, Stroke, and Myocardial Infarction in the United States
National Bureau of Economic Research Working Paper
June 14, 2021
May 5, 2021